Profectus BioSciences Inc., a biotechnology company specializing in research and development of vaccines, will locate a research laboratory in Tarrytown, New York, according to state economic development officials. The company plans to hire 13 research scientists immediately, with plans for an additional 20 jobs over the next two years. Maryland-headquartered Profectus is planning to begin clinical trials on an HIV vaccine later this year or early next year, and has received funding and vaccine acquisitions from Wyeth Pharmaceuticals; the Journal News of the Lower Hudson Valley reports that the company chose the Westchester County location in part because some of the scientists involved in the project work at Wyeth's Pearl River, New York, facilities. "In addition to our headquarters in Baltimore, Maryland, this new location allows us to significantly expand our operations and advance clinical development of therapeutic and preventative vaccines for chronic viral diseases," says Shawn Patrick O'Brien, Profectus' president and CEO. "We are grateful for the opportunity to work with Empire State Development and look forward to establishing our presence in one of the leading biotech communities." The state will provide a $105,000 grant to the company; no information was released regarding the company's investment, but state officials say that the company will renovate existing space.